| 阮倩倩,李 艺.双歧杆菌三联活菌散在儿童消化性溃疡中的应用效果分析[J].中国烧伤创疡杂志,2025,(2):161~165. |
| DOI： |
| 中文关键词: 消化性溃疡 儿童 双歧杆菌三联活菌散 幽门螺杆菌 |
| 英文关键词:Peptic ulcer Children Bifidobacterium triple viable powder Helicobacter pylori |
| 基金项目: |
|
| 摘要点击次数: 0 |
| 全文下载次数: 0 |
| 中文摘要: |
| 【摘要】 目的 分析双歧杆菌三联活菌散在儿童消化性溃疡中的应用效果。方法 选取 2021 年3月至2024年3月南阳市中心医院收治的94例消化性溃疡患儿作为研究对象, 按照不同治疗方法将其分为观察组(47例)与对照组(47例), 观察组患儿采用双歧杆菌三联活菌散联合四联疗法治疗, 对照组患儿单纯采用四联疗法治疗, 对比观察两组患儿血清炎症因子与生长因子水平、肠道菌群含量、双歧杆菌属/肠杆菌属(B/ E)值、幽门螺杆菌根除情况以及临床疗效。结果 治疗 2、4 周后, 观察组患儿血清干扰素-γ ( IFN-γ)、肿瘤坏死因子-α(TNF-α)、C反应蛋白 ( CRP) 水平均低于对照组 (治疗 2 周: t = 2.156、2.790、2.963, P = 0.034、0.006、0.004; 治疗4周: t = 2.709、3.333、2.977, P = 0.008、0.001、0.004), 血清转化生长因子-β1 (TGF-β1)、碱性成纤维细胞生长因子(bFGF)、血管内皮生长因子(VEGF)水平均高于对照组 (治疗 2 周: t = 3.821、6.220?6.746, P均<0.001;治疗4周: t = 2.911、3.653、3.918, P = 0.005、P<0.001、P<0.001), 产气荚膜梭菌含量低于对照组 (t = 4.261、7.459, P均<0.001), 乳酸菌、双歧杆菌含量以及B/ E值均高于对照组 (治疗2周: t =3.722、5.687、6.449, P 均<0.001; 治疗4周: t = 8.139、13.450、14.350, P均<0.001); 治疗4周后, 观察组患儿幽门螺杆菌根除率及临床疗效与对照组均无明显差异 ( χ2/ Z = 3.642、-1.854, P = 0.056、0.064)。结论在四联疗法基础上联合应用双歧杆菌三联活菌散能够明显降低消化性溃疡患儿机体炎症因子水平、提高生长因子水平、改善肠道菌群结构, 为溃疡愈合创造有利条件。 |
| 英文摘要: |
| 【Abstract】 Objective To analyze the effect of bifidobacterium triple viable powder application in children with peptic ulcer. Methods 94 children with peptic ulcer admitted to Nanyang Central Hospital from March 2021 to March 2024 were enrolled as research subjects and divided into study group (n = 47) and control group (n = 47) based on different treatment methods. Children in the study group were treated with bifidobacterium triple viable powder combined with quadruple therapy, whereas children in the control group were treated with quadruple therapy alone. The levels of serum inflammatory and growth factors, intestinal flora content, Bifidobacterium/ Enterobacterium (B/ E) ratio, Helicobacter pylori eradication rate, and clinical efficacy were compared between the two groups. Results After 2 and 4 weeks of treatment, the serum interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and C-reactive protein (CRP) levels of the children in the study group were lower than those in the control group (2 weeks of treatment: t = 2.156, 2.790 and 2.963, P = 0.034, 0.006 and 0.004; 4 weeks of treatment: t = 2.709, 3.333 and 2.977, P= 0.008, 0.001 and 0.004). The levels of serum trans-forming growth factor-β1 ( TGF-β1), basic fibroblast growth factor ( bFGF), and vascular endothelial growth factor (VEGF) were higher than those in the control group (2 weeks of treatment: t = 3.821, 6.220 and 6.746, all P<0.001; 4 weeks of treatment: t = 2.911, 3.653 and 3.918, P = 0.005, P< 0.001, P< 0.001). Clostridium perfringens level was lower than that of the control group (t = 4.261 and 7.459, both P<0.001). Lactobacilli and bifidobacteria levels as well as B/ E ratio were higher than those of the control group (2 weeks of treatment: t = 3.722, 5.687 and 6.449, all P<0.001; 4 weeks of treatment: t = 8.139, 13.450 and 14.350, all P<0.001). After 4 weeks of treatment, there was no significant difference in Helicobacter pylori eradication rate or clinical efficacy of the children between the two groups ( χ2/ Z = 3.642 and -1.854, P= 0.056 and 0.064). Conclusion The combination of bifidobacterium triple viable powder and quadruple therapy can significantly reduce inflammatory factor levels, increase growth factor levels, and improve the structure of the intestinal flora in children with peptic ulcer, creating favorable conditions for ulcer healing. |
|
|
|
|
